Oisin Biotechnologies is a pioneering company in the biotechnology sector, focusing on developing advanced therapies to combat age-related conditions. The company leverages its proprietary Proteo Lipid Vehicle (PLV) technology, which allows for extensive distribution of DNA and RNA payloads beyond the liver and enables safe, repeated dosing. Oisin's core programs aim to address frailty by stimulating muscle growth, selectively eliminating fat cells, and removing senescent cells, which are cells that have stopped dividing and contribute to aging and various diseases.

Oisin Biotechnologies primarily serves the healthcare and pharmaceutical markets, targeting patients suffering from age-related conditions and diseases. The business model revolves around research and development, with revenue generated through partnerships, licensing agreements, and potentially direct sales of its therapeutic solutions.

The company operates in a highly specialized market, focusing on innovative solutions that address significant unmet medical needs. By utilizing its unique PLV technology, Oisin aims to provide safer and more effective treatments compared to traditional viral delivery methods.

Keywords: biotechnology, frailty, muscle growth, fat cell elimination, senescent cells, PLV technology, DNA payloads, RNA payloads, age-related conditions, healthcare.